Tìm theo
Octreotide
Các tên gọi khác (3) :
  • Octreotida
  • Octreotidum
  • Octrotide
Thuốc chống ung thư và tác động vào hệ thống miễn dịch
Thuốc Gốc
Small Molecule
CAS: 83150-76-9
ATC: H01CB02
ĐG : APP Pharmaceuticals , http://www.apppharma.com
CTHH: C49H66N10O10S2
PTK: 1019.239
Octreotide is the acetate salt of a cyclic octapeptide. It is a long-acting octapeptide with pharmacologic properties mimicking those of the natural hormone somatostatin.
Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
C49H66N10O10S2
Phân tử khối
1019.239
Monoisotopic mass
1018.440479762
InChI
InChI=1S/C49H66N10O10S2/c1-28(61)39(25-60)56-48(68)41-27-71-70-26-40(57-43(63)34(51)21-30-13-5-3-6-14-30)47(67)54-37(22-31-15-7-4-8-16-31)45(65)55-38(23-32-24-52-35-18-10-9-17-33(32)35)46(66)53-36(19-11-12-20-50)44(64)59-42(29(2)62)49(69)58-41/h3-10,13-18,24,28-29,34,36-42,52,60-62H,11-12,19-23,25-27,50-51H2,1-2H3,(H,53,66)(H,54,67)(H,55,65)(H,56,68)(H,57,63)(H,58,69)(H,59,64)/t28-,29?,34-,36+,37+,38-,39-,40+,41+,42+/m1/s1
InChI Key
InChIKey=DEQANNDTNATYII-RRCPSWKPSA-N
IUPAC Name
(4R,7S,10S,13R,16S,19R)-19-[(2R)-2-amino-3-phenylpropanamido]-10-(4-aminobutyl)-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide
Traditional IUPAC Name
(4R,7S,10S,13R,16S,19R)-19-[(2R)-2-amino-3-phenylpropanamido]-10-(4-aminobutyl)-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide
SMILES
C[C@@H](O)[C@@H](CO)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@H](N)CC2=CC=CC=C2)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@H](CC2=CNC3=C2C=CC=C3)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)O)C(=O)N1
Độ hòa tan
1.22e-02 g/l
logP
1
logS
-4.9
pKa (strongest acidic)
11.4
pKa (Strongest Basic)
10.17
PSA
332.22 Å2
Refractivity
269.77 m3·mol-1
Polarizability
105.28 Å3
Rotatable Bond Count
17
H Bond Acceptor Count
12
H Bond Donor Count
13
Physiological Charge
2
Number of Rings
5
Bioavailability
0
MDDR-Like Rule
true
Dược Lực Học : Octreotide exerts pharmacologic actions similar to the natural hormone, somatostatin. It is an even more potent inhibitor of growth hormone, glucagon, and insulin than somatostatin. Like somatostatin, it also suppresses leuteinizing hormone (LH) response to GnRH, decreases splanchnic blood flow, and inhibits release of serotonin, gastrin, vasoactive intestinal peptide, secretin, motilin, and pancreatic polypeptide. Octreotide has been used to treat the symptoms associated with metastatic carcinoid tumors (flushing and diarrhea), and Vasoactive Intestinal Peptide (VIP) secreting adenomas (watery diarrhea). Octreotide substantially reduces and in many cases can normalize growth hormone and/or IGF-1 (somatomedin C) levels in patients with acromegaly.
Cơ Chế Tác Dụng : Octreotide is the acetate salt of a cyclic octapeptide. It is a long-acting octapeptide with pharmacologic properties mimicking those of the natural hormone somatostatin. Octreotide binds to somatostatin receptors. These receptors are coupled via pertussis toxin sensitive G proteins which lead to inhibition of adenylyl cyclase. Octreotide binding to these receptors also stimulates phosphotyrosine phosphatase and activation of the Na(+)/H(+) exchanger via pertussis toxin insensitive G proteins.
Dược Động Học :

▧ Volume of Distribution :
* 13.6 L [healthy volunteers] * 21.6±8.5 L [patients with acromegaly]
▧ Route of Elimination :
About 32% of the dose is excreted unchanged into the urine.
▧ Clearance :
* 7 – 10 L/hr [healthy after 100-mcg SC injection] * 18 L/hr [patients with acromegaly after 100-mcg SC injection] * 8.8 L/hr [mild renal impairment after 100-mcg SC injection] * 7.3 L/hr [moderate renal impairment after 100-mcg SC injection] * 7.6 L/hr [severe renal impairment after 100-mcg SC injection] * 4.5 L/hr [severe renal failure requiring dialysis after 100-mcg SC injection] * 5.9 L/hr [Patients with liver cirrhosis after 100-mcg SC injection] * 8.2 L/hr [patients with fatty liver disease after 100-mcg SC injection]
Chỉ Định : For treatment of acromegaly and reduction of side effects from cancer chemotherapy
Tương Tác Thuốc :
  • Artemether Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Cyclosporine Octreotide decreases the effect of cyclosporine
  • Dihydrocodeine Concurrent use may enhance the analgesic effect of dihydrocodeine. It is recommended to monitor therapy, and reduce the dose of dihydrocodeine as appropriate.
  • Insulin Lispro Concomitant therapy with somatostatin analogs may increase the blood-glucose-lowering effect of insulin lispro and thus the chance of hypoglycemia should be monitored closely.
  • Lumefantrine Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
  • Quinupristin This combination presents an increased risk of toxicity
  • Tacrolimus Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
  • Thiothixene May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
  • Toremifene Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
  • Trimipramine Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
  • Voriconazole Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
  • Vorinostat Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
  • Ziprasidone Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
  • Zuclopenthixol Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Liều Lượng & Cách Dùng : Powder - Intramuscular
Solution - Intravenous
Dữ Kiện Thương Mại
Giá thị trường
Nhà Sản Xuất
Đóng gói
Tài Liệu Tham Khảo Thêm
drugbank
http://www.drugbank.ca/drugs/DB00104
KEGG Compound
http://www.genome.jp/dbget-bin/www_bget?cpd:C07306
KEGG Drug
http://www.genome.jp/dbget-bin/www_bget?drug:D00442
BindingDB
http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50175592
National Drug Code Directory
http://www.hipaaspace.com/Medical_Billing/Coding/National.Drug.Codes/PDF/0078-0180-01
PharmGKB
http://www.pharmgkb.org/drug/PA450678
Wikipedia
http://en.wikipedia.org/wiki/Octreotide
RxList
http://www.rxlist.com/cgi/generic/octreotide.htm
Drugs.com
http://www.drugs.com/cdi/octreotide.html
... loading
... loading